AVT03 Gains EMA Positive Opinion

  Published 8 months ago

Dr. Reddy's AVT03 biosimilar gets EMA CHMP positive opinion, pending European Commission approval for marketing.

  • AVT03 mirrors Prolia and Xgeva, targeting osteoporosis and cancer bone metastasis treatments across European markets.
  • Dr. Reddy's holds semi‑exclusive European rights, while Alvotech co‑develops and distributes the biosimilar in collaboration.
  • UK MHRA approval will follow via the International Recognition Procedure after European authorization is confirmed successfully.

You might like these

Indo Thai Securities Q2 26 Profit Surge

JSW Cement IPO Subscribed 0.29x on Day 1

Blue Dart Q1 PBT Falls 8.5% YoY

CreditAccess Grameen Shares Soar 6.6% on Record Disbursements, Improved Asset Quality

Trump Tariffs Hit Indian Textile Stocks

Entero Healthcare Shares Fall on Downgrade

India PMI Shows Slower Service Growth

News that matters the most ⚡